App-Quantinova.ai

Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Jai N Patel - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bosutinib

5-Azacytidine and Venetoclax Combination Boost Vγ9Vδ2 T Cell Effector Functions

Anne-Charlotte Le Floch - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

5-Azacytidine

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Justin Layer - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pevonedistat

A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

Bernd Schlereth - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

monomethyl auristatin E

Mechanistic Study of Wee1 Kinase Inhibition with AZD1775 Exposes Drug Targetable Vulnerabilities in Acute B-Lymphoblastic Leukemia

Alena Malyukova - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

dasatinib

Preclinical Studies of Chiauranib Inhibit Follicular Lymphoma through VEGFR2/ERK/STAT3 Signaling Pathway

Yuanfang Tang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

chiauranib

Hemostatic Profile at Diagnosis in Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis of Cases from the Literature

Paul Thuan Tieu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Solid malignancies

Hemostatic Solution

Dermatologic Adverse Events in Acute Lymphocytic Leukemia Patients Treated with Bispecific T-Cell Engager Blinatumomab

Rose Parisi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Blinatumomab

Characteristics and Outcomes for Adult Patients with T-Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): A Retrospective Study

Julian Hardy McLain - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outcomes in Hispanic Patients with Philadelphia-Negative and Philadelphia-like Acute Lymphoblastic Leukemia with the Use of Blinatumomab

Abdullah Ladha - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Blinatumomab

Time to Diagnosis and Treatment in an Underserved, Predominantly Hispanic Population of Adults in East Los Angeles- a Retrospective Study of Acute T- Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Patients

Madeline MacDonald - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Vitamin D Levels in Pediatric Patients Undergoing Chemotherapy

Madison K Schoeberl - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ergocalciferol

United Arab Emirates Population-Based Acute Leukaemia Registry: Acute Lymphoblastic Leukaemia Real-World Data

Waed Jaber - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Cyclophosphamide

NUP98-HOXA9 Bearing Acute Myeloid Leukemia

Yi Fang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

Vidaza

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Irene Graf - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

ara-c

Changing Frontline AML Treatment Patterns in Alberta, Canada from 2013 - 2022

Kurt Ebeling - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Azacitidine

A Comparative Study between Acute Myeloid Leukemia in Adolescent and Young Adults (AYA) Versus Non-AYA Patients: Single Center Experience

Shehab Fareed Mohamed - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Overview of Acute Myeloid Leukemia in Adults at the Peruvian National Cancer Institute (INEN)

Melanie Castro-Mollo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinicopathologic Characteristics and Outcome of Acute Myeloid Leukemia with (AML) with Core Binding Factor (CBF) Rearrangements: A Retrospective Study

Shehab Fareed Mohamed - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML): A Single Center Experience

Shehab Fareed Mohamed - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts